Gut Microbiome-Modulating therapeutics and lipid profile in metabolic syndrome: A systematic review and meta-analysis of clinical trials.
Pradipta Paul, Ridhima Kaul, Muhammad Ayyan et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the impact of gut microbiome-modulating interventions on lipid profiles in adults with metabolic syndrome. Nineteen studies with 897 participants were analyzed, revealing significant reductions in total cholesterol (MD -8.97 mg/dL) and triglycerides (MD -11.33 mg/dL), while HDL-C remained unchanged. LDL-C reduction was noted but less certain due to high heterogeneity.
Key findings
- Total cholesterol decreased by MD -8.97 mg/dL (95% CI -12.55 to -5.38).
- Triglycerides were reduced by MD -11.33 mg/dL (95% CI -19.25 to -3.40).
- LDL-C showed a reduction of MD -5.05 mg/dL (95% CI -9.57 to -0.53), but with high heterogeneity.
- Higher probiotic doses and longer interventions generally led to greater lipid reductions.
Why it matters
Understanding the effects of gut microbiome-modulating therapies on lipid profiles can inform treatment strategies for metabolic syndrome, a condition linked to increased cardiovascular risk. Clinicians may consider these interventions as part of a comprehensive management plan.
What to keep in mind
The study noted substantial heterogeneity in LDL-C results and variability in moderator effects across lipid outcomes.